Cure8 research brief
Why This Matters
The review proposes S100B as a molecular link connecting enteric glial activation, intestinal barrier dysfunction, and liver/brain inflammation. If confirmed, this could help explain symptom overlap between gut and liver/brain complications and point to new biomarker or therapeutic research directions.
Who Should Pay Attention
Clinicians and researchers working on IBD, gut–liver interactions, and neurogastroenterology; adult patients interested in biologic mechanisms behind gut–brain symptoms.
Study Snapshot
What To Know
This is a narrative review (abstract-level summary provided). It synthesizes preclinical and clinical evidence that S100B acts both as a homeostatic factor at low levels and as an inflammatory "alarmin" when chronically elevated, engaging receptors such as RAGE, TLR2/4, and inflammasome pathways (NLRP3).
The authors discuss S100B presence in enteric glia, brain astrocytes, and certain liver cells and link its kinetics to acute versus chronic disease states like cirrhosis, IBD, IBS-D, and hepatic encephalopathy.
The review frames S100B as a candidate biomarker and mechanistic bridge in the brain–gut–liver axis, but emphasizes that causal roles, tissue sources, and clinical utility remain to be validated.
Keep In Mind
The source is a review article (Frontiers in Immunology) summarized at the abstract level; it compiles existing preclinical and clinical studies but does not establish definitive clinical utility for S100B.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.